Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.53. Xtant Medical shares last traded at $0.52, with a volume of 94,800 shares changing hands.

Wall Street Analyst Weigh In

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the company a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Trading Down 1.3 %

The stock has a market cap of $67.60 million, a PE ratio of -25.94 and a beta of 0.39. The company has a current ratio of 2.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.49.

Institutional Trading of Xtant Medical

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Evernest Financial Advisors LLC purchased a new stake in Xtant Medical during the 3rd quarter valued at about $27,000. Juniper Investment Company LLC purchased a new stake in Xtant Medical during the 1st quarter valued at about $408,000. Finally, Vanguard Group Inc. grew its stake in Xtant Medical by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock valued at $1,812,000 after acquiring an additional 48,319 shares in the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.